Indoor dining will return to New York City on Valentine’s Day at 25% capacity, New York Gov. Andrew Cuomo said Friday.

Indoor dining was shut down in New York City in December.

On March 15, in-person weddings can resume in New York at 50% capacity, or up to 150 people, he said.

Meanwhile, in hard-hit Los Angeles County, outdoor dining is now allowed to reopen at 50% capacity, but with a restriction: TVs must remain off.

Dr. Jay Butler, deputy director for infectious diseases at the Centers for Disease Control and Prevention, said Friday the U.S. has seen a decline in the last two weeks of new cases and hospitalizations, which is “encouraging." But, he added, "The numbers nationally are still high."

"The pandemic is not yet over yet," Butler told the Infectious Diseases Society of America. "By the time we end our 45 minutes together, roughly 100 more Americans will have died of COVID-19."

Butler stressed that the vaccines are safe and effective and that mild side effects are normal.

"The available data tells us that more than half of people have reported some degree of tiredness and pain at the injection site, although most are able to continue normal daily activities," Butler said. "Many also report symptoms such as headache, muscle pain or chills after getting their shots, particularly in the first couple of days. These data also suggest that it may be more common among younger persons after the second dose, but again, this is expected based on some of the data that were available from the clinical trials."

ABC News’ Sophie Tatum contributed to this report.

AstraZeneca’s vaccine on Friday was recommended for conditional marketing authorization in the European Union for people 18 and older. The vaccine is given as two doses.

This is the third vaccine, following Pfizer and Moderna, to be approved by the European Medicines Agency. The AstraZeneca vaccine now awaits final say from the European Commission.

In another promising development for vaccine science, Johnson & Johnson announced Friday that its COVID-19 vaccine -- a single shot tested against a complex barrage of newly emerged variants of the virus -- is 66% effective at preventing symptomatic disease and 85% effective against preventing severe illness.

The U.S. pharmaceutical giant said the vaccine is also safe to take. Volunteers experienced mild reactions after the shot, with less than 10% experiencing fever, according to a company press release.

The full data package will be made publicly available and will be evaluated by the FDA's advisory committee sometime in mid- to late February.

The Food and Drug Administration has said it will consider a vaccine that's more than 50% effective, and the Johnson & Johnson vaccine exceeds this threshold. An emergency use authorization could be given and people could start receiving shots before the end of February.

ABC News' Sony Salzman contributed to this report.

The United States’ first known cases of the South Africa variant of the novel coronavirus have been confirmed in two people in South Carolina, according to the South Carolina Department of Health and Environmental Control.

"There is no known travel history and no connection between these two cases," the department said in a statement Thursday.

Both cases are among adults, one who is from the Lowcountry region and another who is from the Pee Dee region, according to the department.

The U.S. Centers for Disease Control and Prevention said it's aware of the cases and it "recommends that people avoid travel at this time."

The so-called B1351 variant, first identified in South Africa, has been detected in more than 30 countries, according to the South Carolina Department of Health and Environmental Control.

"Experts agree that existing vaccines work to protect us from this variant, even if we don’t know precisely how effective they are," the department said. "At this time, there’s no evidence to suggest that the B.1.351 variant causes more severe illness."

During an interview Thursday on ABC's "Good Morning America," Dr. Anthony Fauci, chief medical adviser to U.S. President Joe Biden and the nation's leading infectious disease expert, said the South Africa variant "troubles" him.

Fauci said lab experiments show the neutralizing antibodies induced by existing COVID-19 vaccines are "diminished by multifold" when tested against the B1351 variant

"It's still within the range of what you would predict to be protective," he said, "but I take no great comfort in that."

However, scientists are already working on vaccines that will specifically target the South Africa variant, according to Fauci.

"May not be necessary," he said, "but if it is we'll already be on the road to be able to give people a boost that directs against the South African isolate."